about
Combining Data From Liver Disease Scoring Systems Better Predicts Outcomes of Patients With Alcoholic Hepatitis.Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases.Review article: intra-arterial treatments in patients with hepatocellular carcinoma.Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death.Lack of association between HFE gene mutations and hepatocellular carcinoma in patients with cirrhosisLiver angiogenesis as a risk factor for hepatocellular carcinoma development in hepatitis C virus cirrhotic patients.Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity In Vitro.Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series.Chemokine RANTES promoter dimorphisms and hepatocellular carcinoma occurrence in patients with alcoholic or hepatitis C virus-related cirrhosis.Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepCharacteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases.Prevalence and clinical significance of nodular regenerative hyperplasia in liver biopsies.Usefulness of routine analysis of ascitic fluid at the time of therapeutic paracentesis in asymptomatic outpatients. Results of a multicenter prospective study.Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir).Sequential Serum Metabolomic Profiling after Radiofrequency Ablation of Hepatocellular Carcinoma Reveals Different Response Patterns According to Etiology.BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease.Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: a modeling approach.Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis.[Reactivation of viral hepatitis C during autoimmune hepatitis treated by immunosuppressive agents].Myeloperoxidase and superoxide dismutase 2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alcoholic cirrhosis.PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis.[Practical screening and early treatment of hepatocellular carcinoma. Results of a French survey].Impact of cytokine gene variants on the prediction and prognosis of hepatocellular carcinoma in patients with cirrhosis.Intermediate hepatobiliary cells predict an increased risk of hepatocarcinogenesis in patients with hepatitis C virus-related cirrhosis.PNPLA3 (rs738409 C>G) is a common risk variant associated with hepatocellular carcinoma in alcoholic cirrhosis.Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcohol-related cirrhosis.Serum albumin and platelet count but not portal pressure are predictive of death in patients with Child-Pugh A hepatitis C virus-related cirrhosis.Genetic dimorphism in superoxide dismutase and susceptibility to alcoholic cirrhosis, hepatocellular carcinoma, and death.Eating Patterns in Patients with Compensated Cirrhosis: A Case-Control Study.Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations.ESM-1 expression in stromal cells is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma.Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis.Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance.Determination of candidate metabolite biomarkers associated with recurrence of HCV-related hepatocellular carcinoma.[Care pathway of patients with hepatocellular carcinoma in France: State of play in 2017].Serum proteoglycans as prognostic biomarkers of hepatocellular carcinoma in patients with alcoholic cirrhosis.Bone mineral density assessed by dual-energy X-ray absorptiometry in patients with viral or alcoholic compensated cirrhosis. A prospective study.The CRP level and STATE score predict survival in cirrhotic patients with hepatocellular carcinoma treated by transarterial embolization.Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma.
P50
Q30942640-F328B9AC-CBBA-403C-8AA8-932AB1986597Q34585594-75B95A3E-6A4F-4D46-A48B-77AE660AA628Q35145069-31F8394D-A4B8-408B-B2EE-B0F72E7C395EQ35360310-69A60A14-C20B-4B60-9E6D-48187C1E0848Q35595951-2F441017-42EB-4E3E-A78F-A77A2E1569BEQ35615755-638FB60C-ABD8-4FA9-8EC3-662DE8300994Q38714435-292C05A0-D761-4234-9F10-1413A0AA65E0Q39250270-405E8518-B2F8-4C52-A726-89044C3D294EQ39269869-27A5472D-F59A-4B1B-9108-13E00353E6A1Q39746873-E21E81B3-8F7A-4A70-A841-B4D6D01F6F59Q40245207-C4F3C6B6-0DA6-4003-9E8D-6F2585677AE4Q40319656-62916AF6-519E-4229-9E91-97F6C83E9934Q40491093-6C5F982B-533E-4C7E-9F3A-3C764F70D9DCQ40509469-94EFC6CA-538A-4CA7-A04C-75A749E7B60BQ40680346-DA15701A-83ED-49DB-95FA-BA8C114DCA69Q40833423-C5CD201D-B990-4630-A17B-131062EDC80EQ41925341-ABE3E52A-EB95-497E-B5A5-73A99A174C70Q42228465-451A8C95-B75D-4807-A1E9-FB090BD61BA1Q42979594-B109BE5C-3566-4F91-BAD6-5F1652E4078CQ43147462-A949146E-75ED-452D-9917-ACCE0BA5363EQ43280918-B75B8947-14C1-488F-9C6E-79E8A544E651Q43611915-7E906250-190F-4CE2-9EE2-607092BD911DQ44113100-61EF703F-46FB-4813-BC6C-3051D034A774Q44391171-45B69319-9C0F-40A8-86C1-476B0B71FD13Q44410161-5840C08C-8333-4247-9E47-8E1C7DF52C58Q44635062-393F89FA-B56B-4A9D-B457-FFD64300A786Q45392148-E683A08A-C469-435C-BB41-7E03C723722FQ45472005-24BEC615-1551-4D5F-95EB-ED91687674A5Q46376179-5D36217C-DE2B-4231-912B-04854122CDA3Q47556068-6FD26613-05F7-444D-8028-E360AE9E94A2Q47650366-BF4FAA4C-5F42-4BA6-9CFE-DEA79E219A35Q47825139-333AB030-5B1E-44DA-BEDA-9D65E8EA0150Q48284910-DEB94B25-1C46-402E-9B4B-5C069468D880Q48341630-6C05EA33-5A79-4278-9AD5-0ACA8380FBFBQ49787544-C3FB4FDF-5C7D-4854-B1AD-3662F0D22256Q50518147-27D5F52C-92D1-4DAF-BBBD-95304B95416CQ50895861-1C951316-6AA9-495A-B629-D6C3A17C5871Q51421623-288B560D-80CE-452C-951D-9FA656378024Q51665394-E7727D35-ADAD-4FE6-B5E8-4E7B79B2AE16Q52666629-A06A6420-E4D2-4E30-9CDC-109CE047B6BE
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nathalie Ganne
@ast
Nathalie Ganne
@en
Nathalie Ganne
@es
Nathalie Ganne
@nl
Nathalie Ganne
@sl
type
label
Nathalie Ganne
@ast
Nathalie Ganne
@en
Nathalie Ganne
@es
Nathalie Ganne
@nl
Nathalie Ganne
@sl
prefLabel
Nathalie Ganne
@ast
Nathalie Ganne
@en
Nathalie Ganne
@es
Nathalie Ganne
@nl
Nathalie Ganne
@sl
P106
P1153
7004296674
P21
P31
P496
0000-0002-7351-5027